1. Academic Validation
  2. Kaposi sarcoma-associated herpesvirus cooperates with Epstein-Barr virus to co-transform a small set of human B cells oncogenically

Kaposi sarcoma-associated herpesvirus cooperates with Epstein-Barr virus to co-transform a small set of human B cells oncogenically

  • PLoS Pathog. 2025 Jun 23;21(6):e1013281. doi: 10.1371/journal.ppat.1013281.
Mitchell Hayes 1 Wei Wang 2 Isabela Fraga de Andrade 1 Paul F Lambert 1 Bill Sugden 1
Affiliations

Affiliations

  • 1 McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • 2 Department of Microbiology, Genetics, & Immunology, Michigan State University, East Lansing, Michigan, United States of America.
Abstract

KSHV has not been found to transform human B cells alone. We show now it infects both peripheral and tonsillar B cells inefficiently and cooperates with EBV to co-transform a similar, small fraction of cells from both sources. These cells yield immortalized progeny, one hallmark of transformation, and depend on both viruses for their continued growth. The cells secrete multiple cytokines that support their paracrine growth and express viral genes that mediate expression of these cytokines. The co-transformed cells grow preferentially as tumors in the peritoneal cavities of NSG mice outgrowing B cells transformed only by EBV. The levels of EBV genes expressed in co-transformed cells decrease during growth in vitro and more so during tumor growth in vivo while those of KSHV increase, mirroring that found In Primary Effusion Lymphoma (PEL) derived cell lines. The expression of cellular genes changes too, to reflect that of PEL biopsies. Both KSHV and EBV oncogenes are expressed in the co-transformed cells that regulate the gene signature of PELs, making these co-transformed cells a tractable model with which to understand this unique lymphoma associated with these two tumor viruses. Studies of this model will also illuminate the individual contributions of each virus to the many cancers they cause.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-16379
    99.93%, JAK2/FLT3 Inhibitor